New monthly shot could tame rare kidney disease
NCT ID NCT07020923
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called atacicept given once a month to people with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if monthly dosing lowers harmful antibodies and reduces protein in the urine, which are signs of kidney damage. About 90 adults are taking part in this Phase 2 trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- atacicept
- What this could lead to
- If successful, this could lead to a more convenient monthly dosing option for controlling IgA nephropathy, potentially slowing kidney damage.
- What could go wrong
- This is an early Phase 2 study with only 90 participants, so results may not confirm effectiveness or safety. The drug may not reduce protein in urine enough to benefit patients long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BERGER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vera Therapeutics
Brisbane, California, 94005, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tame autoimmune kidney disease?
- Can an Anti-Inflammatory diet protect the kidneys? a trial puts the autoimmune protocol to the test
- Atacicept's Long-Term promise for kidney disease
- Scientists investigate mysterious loin pain in kidney disease
- New hope for kidney patients: drug aims to prevent relapse
- 800-Patient study aims to uncover best treatments for kidney disease